81 related articles for article (PubMed ID: 26185017)
21. Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.
Sehouli J; Stengel D; Harter P; Kurzeder C; Belau A; Bogenrieder T; Markmann S; Mahner S; Mueller L; Lorenz R; Nugent A; Wilke J; Kuznik A; Doering G; Wischnik A; Sommer H; Meerpohl HG; Schroeder W; Lichtenegger W; Oskay-Oezcelik G
J Clin Oncol; 2011 Jan; 29(2):242-8. PubMed ID: 21115872
[TBL] [Abstract][Full Text] [Related]
22. Carboplatin versus cisplatin in ovarian cancer.
Alberts DS
Semin Oncol; 1995 Oct; 22(5 Suppl 12):88-90. PubMed ID: 7481869
[TBL] [Abstract][Full Text] [Related]
23. Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group.
Fotopoulou C; duBois A; Karavas AN; Trappe R; Aminossadati B; Schmalfeldt B; Pfisterer J; Sehouli J;
J Clin Oncol; 2008 Jun; 26(16):2683-9. PubMed ID: 18509180
[TBL] [Abstract][Full Text] [Related]
24. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.
Gershenson DM; Sun CC; Bodurka D; Coleman RL; Lu KH; Sood AK; Deavers M; Malpica AL; Kavanagh JJ
Gynecol Oncol; 2009 Jul; 114(1):48-52. PubMed ID: 19361839
[TBL] [Abstract][Full Text] [Related]
25. Sexuality as a Prognostic Factor-Results of an Individual Patient Data NOGGO (North-Eastern German Society of Gynecological Oncology)-Meta-Analysis of 644 Recurrent Ovarian Cancer Patients Prior to Chemotherapy.
Balint N; Woopen H; Richter R; Pirmorady-Sehouli A; Pietzner K; Sehouli J
Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398202
[TBL] [Abstract][Full Text] [Related]
26. Analysis of docetaxel therapy in elderly (≥70 years) castration resistant prostate cancer patients enrolled in the Netherlands Prostate Study.
Gerritse FL; Meulenbeld HJ; Roodhart JM; van der Velden AM; Blaisse RJ; Smilde TJ; Erjavec Z; de Wit R; Los M;
Eur J Cancer; 2013 Oct; 49(15):3176-83. PubMed ID: 23849828
[TBL] [Abstract][Full Text] [Related]
27. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.
Gray HJ; Shah CA; Swensen RE; Tamimi HK; Goff BA
Gynecol Oncol; 2010 Mar; 116(3):340-4. PubMed ID: 19922987
[TBL] [Abstract][Full Text] [Related]
28. Retrospective analysis of the impact of platinum dose reduction and chemotherapy delays on the outcomes of stage III ovarian cancer patients.
Liutkauskiene S; Janciauskiene R; Jureniene K; Grizas S; Malonyte R; Juozaityte E
BMC Cancer; 2015 Mar; 15():105. PubMed ID: 25879527
[TBL] [Abstract][Full Text] [Related]
29. Systemic therapy for ovarian cancer: current status and new treatments.
Ozols RF
Semin Oncol; 2006 Apr; 33(2 Suppl 6):S3-11. PubMed ID: 16716797
[TBL] [Abstract][Full Text] [Related]
30. Long time therapy with topotecan in patients with recurrence of ovarian carcinoma.
Möbus V; Pfaff PN; Volm T; Kreienberg R; Kaubitzsch S
Anticancer Res; 2001; 21(5):3551-6. PubMed ID: 11848522
[TBL] [Abstract][Full Text] [Related]
31. Centralized treatment of advanced stages of ovarian cancer improves survival: a nationwide Danish survey.
Fagö-Olsen CL; Høgdall C; Kehlet H; Christensen IJ; Ottesen B
Acta Obstet Gynecol Scand; 2011 Mar; 90(3):273-9. PubMed ID: 21306310
[TBL] [Abstract][Full Text] [Related]
32. Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer.
Ozols RF
Semin Oncol; 2000 Jun; 27(3 Suppl 7):3-7. PubMed ID: 10952119
[TBL] [Abstract][Full Text] [Related]
33. [Phase II clinical study of topotecan hydrochloride in patients with recurrent advanced ovarian cancer].
Li JD; Guan ZZ; Liu JH; Xin XY; Cui Y; Huang CJ; Liu FY; Song L; Bian ML; Zhou QH
Ai Zheng; 2002 Apr; 21(4):416-20. PubMed ID: 12452024
[TBL] [Abstract][Full Text] [Related]
34. Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group.
Hochster H; Plimack ER; Runowicz CD; Speyer J; Wallach RC; Sorich J; Mandeli J; Wadler S; Wright J; Muggia FM
J Clin Oncol; 2004 Jan; 22(1):120-6. PubMed ID: 14701774
[TBL] [Abstract][Full Text] [Related]
35. Treatment of elderly ovarian cancer patients in the context of controlled clinical trials: a joint analysis of the AGO Germany experience.
Hilpert F; Wimberger P; du Bois A; Pfisterer J; Harter P
Onkologie; 2012; 35(3):76-81. PubMed ID: 22414969
[TBL] [Abstract][Full Text] [Related]
36. A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
Covens A; Blessing J; Bender D; Mannel R; Morgan M;
Gynecol Oncol; 2006 Mar; 100(3):586-90. PubMed ID: 16249022
[TBL] [Abstract][Full Text] [Related]
37. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial.
Pignata S; Scambia G; Ferrandina G; Savarese A; Sorio R; Breda E; Gebbia V; Musso P; Frigerio L; Del Medico P; Lombardi AV; Febbraro A; Scollo P; Ferro A; Tamberi S; Brandes A; Ravaioli A; Valerio MR; Aitini E; Natale D; Scaltriti L; Greggi S; Pisano C; Lorusso D; Salutari V; Legge F; Di Maio M; Morabito A; Gallo C; Perrone F
J Clin Oncol; 2011 Sep; 29(27):3628-35. PubMed ID: 21844495
[TBL] [Abstract][Full Text] [Related]
38. An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer.
Berry E; Matthews KS; Singh DK; Buttin BM; Lurain JR; Alvarez RD; Schink J
Gynecol Oncol; 2009 Apr; 113(1):63-7. PubMed ID: 19201457
[TBL] [Abstract][Full Text] [Related]
39. Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study.
; Secord AA; Lee PS; Darcy KM; Havrilesky LJ; Grace LA; Marks JR; Berchuck A
Gynecol Oncol; 2006 Jun; 101(3):390-7. PubMed ID: 16551475
[TBL] [Abstract][Full Text] [Related]
40. A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study.
Sabbatini P; Sill MW; O'Malley D; Adler L; Secord AA;
Gynecol Oncol; 2008 Dec; 111(3):455-60. PubMed ID: 18829087
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]